Menu Search
Equities

Bure Equity AB

BLZ:STU

Bure Equity AB

Actions
  • Price (EUR)32.26
  • Today's Change-0.02 / -0.06%
  • Shares traded0.00
  • 1 Year change+64.68%
  • Beta--
Data delayed at least 15 minutes, as of Nov 04 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bure Equity AB is a Sweden-based investment company. The Company specializes in long-term owning, developing, as well as disposing listed and unlisted operating entities. Its holding portfolio comprises eight firms: Cavotec, an engineering group that delivers power transmission, distribution and control technologies to a range of areas; MedCap, which owns and develops companies involved in the Life Science sector; Mycronic, which designs and manufactures laser-based pattern generators that are used in the flexible electronics production; PartnerTech, providing product development, as well as production, logistics and aftermarket services; Vitrolife, a developer and producer of solutions for fertility treatment; XVIVO Perfusion AB, which focuses on organ, tissue and cell preservation in relation with transplantation; Investment AB Bure, which owns and manages leasing of locomotives; and Mercuri International, which offers sales and management training consultancy.

  • Revenue in SEK (TTM)210.00m
  • Net income in SEK6.36bn
  • Incorporated1992
  • Employees12.00
  • Location
    Bure Equity ABNybrogatan 6STOCKHOLM 114 34SwedenSWE
  • Phone+46 86140020
  • Fax+46 86140038
  • Websitehttps://www.bure.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.